2-bromo-5-(ethylsulfanyl)thiophen | 19991-60-7

• 分子结构分类: 有机化合物 - 有机硫化合物 - 硫醚类
• 英文名称: 2-bromo-5-(ethylsulfanyl)thiophen
• 英文别名: 2-bromo-5-ethylsulfanyl-thiophene；2-Brom-5-aethyl-mercapto-thiophen；2-bromo-5-ethylsulfanylthiophene
• CAS: 19991-60-7
• 化学式: C₆H₇BrS₂
• 分子量: 223.158
• InChiKey: RDTLGIMPLIHQRD-UHFFFAOYSA-N

物化性质

• 沸点：
  255.6±25.0 °C(Predicted)
• 密度：
  1.59±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.8
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  53.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  2-bromo-5-(ethylsulfanyl)thiophen 在 Oxone 作用下， 以 四氢呋喃 、 甲醇 、 水 为溶剂， 反应 3.0h， 生成 5-Brom-2-ethylsulfonyl-thiophen
  参考文献：
  名称：

  [EN] HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
  [FR] AGENTS RÉCEPTEURS DE L'HISTAMINE H3, PRÉPARATION ET UTILISATIONS THÉRAPEUTIQUES

  摘要：

  本发明提供了一种新的化合物式(I)或其药学上可接受的盐，具有组胺H3受体拮抗剂或反向激动剂活性，以及制备此类化合物的方法。在另一种实施方案中，本发明还公开了包括化合物式(I)的制药组合物，以及使用它们治疗肥胖症、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。

  公开号：

  WO2006023462A1
• 作为产物：
  描述：

  2-ethylthiophene 生成 2-bromo-5-(ethylsulfanyl)thiophen
  参考文献：
  名称：

  NITROGENOUS FUSED-RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF

  摘要：

  公开号：

  EP1382603B1

文献信息

• HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES
  申请人：Finley Don Richard

  公开号：US20090048225A1

  公开（公告）日：2009-02-19

  The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

  本发明提供一种新型化合物(I)或其药学上可接受的盐，具有组胺H3受体拮抗剂或反向激动剂的活性，以及制备这种化合物的方法。在另一种实施方式中，本发明揭示了包含化合物(I)的药物组合物，以及使用它们治疗肥胖症、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• Histamine H3 Receptor Agents, Preparation and Therapeutic Uses
  申请人：FINLEY Don Richard

  公开号：US20100029608A1

  公开（公告）日：2010-02-04

  The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-113 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

  本发明提供了一种新的化合物（I）或其药学上可接受的盐，具有组胺113受体拮抗剂或反向激动剂活性，以及制备这种化合物的方法。在另一种实施方式中，本发明揭示了包含化合物（I）的制药组合物，以及使用它们治疗肥胖症、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• Histamine H3 receptor agents, preparation and therapeutic uses
  申请人：Eli Lilly and Company

  公开号：US07705025B2

  公开（公告）日：2010-04-27

  The present invention provides a novel compound of Formula (I) or a pharmaceutically acceptable salt thereof, having histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another, embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases.

  本发明提供了一种新的化合物，其化学式为(I)，或其药学上可接受的盐，具有组胺H3受体拮抗剂或反向激动剂活性，并提供了制备这种化合物的方法。在另一个实施例中，本发明还揭示了包括化合物(I)的制药组合物以及使用它们治疗肥胖症、认知缺陷、嗜睡症和其他组胺H3受体相关疾病的方法。
• NITROGENOUS FUSED−RING COMPOUND HAVING PYRAZOLYL GROUP AS SUBSTITUENT AND MEDICINAL COMPOSITION THEREOF
  申请人：Eisai Co., Ltd.

  公开号：EP1382603A1

  公开（公告）日：2004-01-21

  The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. Inparticular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, X represents a nitrogen-containing condensed aromatic heterocyclic group such as imidazo[1,2-a]pyridine, benzimidazole, quinazoline, quinoline, or 2,1-benzisoxazole and has (R4)n as substituent groups; Y represents a C3-8 cycloalkyl group, C4-8 cycloalkenyl group, 5- to 14-membered non-aromatic heterocyclic group, C6-14 aromatic hydrocarbon cyclic group or 5- to 14-membered aromatic heterocyclic group; n in (R4)n is 0, 1, 2 or 3, and Z groups independently represent (1) hydrogen atom, (2) amino group, (3) halogen atom, (4) hydroxyl group, (5) nitro group, (6) cyano group, (7) azido group, (8) formyl group, (9) hydroxyamino group, (10) sulfamoyl group, (11) guanodino group, (12) oxo group, (13) C2-6 alkenyl group, (14) C1-6 alkoxy group, (15) C1-6 alkylhydroxyamino group, (16) halogenated C1-6 alkyl group, (17) halogenated C2-6 alkenyl group, (18) (i) C3-7cycloalkyl group, (ii) C3-7cycloalkenyl group, (iii) 5- to 14-membered non-aromatic heterocyclic group, each of which may have one or more substituent groups Q, or (19) formula -M1-M2-M3, R1 represents (1) hydrogen atom, (2) halogen atom, (3) hydroxyl group, (4) nitro group, (5) cyano group, (6) halogenated C1-6 alkyl group, (7) C2-6 alkyl group substituted with a hydroxyl or cyano group, (8) C2-6 alkenyl group, or (9) formula -L1-L2-L3, and R2 represents a hydrogen atom or a protecting group; and R3 represents a hydrogen atom, halogen atom, cyano group, amino group, C1-4 alkyl group or halogenated C1-4 alkyl group.

  本发明提供了一种对 STAT6 的活化具有极佳抑制作用的化合物及其药物组合物。特别是提供了由下式（I）代表的化合物、其盐或它们的水合物。 式中，X代表含氮缩合芳香杂环基团，如咪唑并[1,2-a]吡啶、苯并咪唑、喹唑啉、喹啉或2,1-苯并异噁唑，并有(R4)n作为取代基；Y代表C3-8环烷基、C4-8环烯基、5～14元非芳香杂环基团、C6-14芳香烃环基或5～14元芳香杂环基团；(R4)n 中的 n 是 0、1、2 或 3，Z 基团独立地代表：(1) 氢原子，(2) 氨基，(3) 卤素原子，(4) 羟基，(5) 硝基，(6) 氰基，(7) 叠氮基，(8) 甲酰基，(9) 羟基氨基、(10) 氨基磺酰基，(11) 氨基胍基，(12) 氧代基，(13) C2-6 烯基，(14) C1-6 烷氧基，(15) C1-6 烷基羟基氨基，(16) 卤代 C1-6 烷基，(17) 卤代 C2-6 烯基，(18) (i) C3-7 环烷基、(ii) C3-7 环烯基，(iii) 5-14 元非芳杂环基团，其中每个基团可有一个或多个取代基 Q，或 (19) 式-M1-M2-M3，R1 代表 (1) 氢原子，(2) 卤素原子，(3) 羟基、(4) 硝基，(5) 氰基，(6) 卤代 C1-6 烷基，(7) 被羟基或氰基取代的 C2-6 烷基，(8) C2-6 烯基，或 (9) 式-L1-L2-L3，R2 代表氢原子或保护基团；R3 代表氢原子、卤素原子、氰基、氨基、C1-4 烷基或卤代 C1-4 烷基。
• Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
  申请人：Eisai R&D Management Co., Ltd.

  公开号：EP2048142A2

  公开（公告）日：2009-04-15

  The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. In particular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them. In the formula, the groups X,Y,Z,R1-R4 and n are defined as in claim 1.

  本发明提供了一种对 STAT6 的活化具有极佳抑制作用的化合物及其药物组合物。特别是提供了由下式（I）代表的化合物、其盐或它们的水合物。 式中，基团 X、Y、Z、R1-R4 和 n 的定义如权利要求 1 所述。